目的：探讨环状RNA hsa_circ_0133159在胶质瘤诊断和预后评估中的临床价值。
方法：采用实时荧光定量反转录聚合酶链反应（quantitative reverse transcription-polymerase chain reaction，qRT-PCR）检测10例正常脑组织和38例胶质瘤组织中hsa_circ_0133159相对表达量，并分析其与胶质瘤患者临床病理特征之间的关系。应用受试者工作特征（receiver operating characteristic，ROC）曲线评估hsa_circ_0133159诊断胶质瘤的临床价值。应用Kaplan-Meier法进行生存分析，log-rank法进行预后的单因素分析，COX回归分析进行预后的多因素分析。
结果：与正常脑组织相比，低级别胶质瘤和高级别胶质瘤组织中hsa_circ_0133159相对表达量均显著增加，差异有统计学意义（P＝0.026，P＝0.007）。ROC曲线评价hsa_circ_0133159诊断胶质瘤的临床价值，其曲线下面积（area under curve，AUC）为0.887，灵敏度和特异度分别为86.8%和80.0%，截断值为4.32。hsa_circ_0133159低表达组（≤4.32，17例）的无进展生存（progression-free survival，PFS）时间和总生存（overall survival，OS）时间均较hsa_circ_0133159高表达组（＞4.32，21例）明显延长。预后的单因素分析显示，Karnofsky能力状态评分、肿瘤病灶数目、肿瘤病理分级、肿瘤是否复发和hsa_circ_0133159相对表达量与胶质瘤患者的PFS和OS显著相关（P＜0.05）。预后的多因素分析显示，hsa_circ_0133159相对表达量是胶质瘤患者的独立预后因素[PFS：相对风险度＝1.268（95%置信区间：1.007～3.459），P＝0.001；OS：相对风险度＝1.252（95%置信区间：1.103～2.422），P＝0.001]。
结论：hsa_circ_0133159可能作为一种新型的生物学标志物应用于胶质瘤的鉴别诊断和预后评估。
Abstract
Objective: To investigate the clinical value of circular RNA hsa_circ_0133159 in diagnosis and prognostic evaluation of glioma.
Methods: The relative expressions of hsa_circ_0133159 in 10 normal brain tissue samples and 38 glioma tissue samples were detected by real-time fluorescence-based quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and its relationship with clinicopathological characteristics was analyzed. The clinical value of hsa_circ_0133159 in diagnosis of glioma was evaluated by using the receiver operating characteristic (ROC) curve. The survival analysis was conducted using Kaplan-Meier method, and the univariate analysis of prognostic factors was conducted by using log-rank test. The multivariate analysis was conducted by using COX regression analysis.
Results: Compared with normal brain tissues, the relative expressions of hsa_circ_0133159 in low-grade and high-grade glioma were increased significantly (P = 0.026, P = 0.007). The area under curve (AUC) of hsa_circ_0133159 in ROC curve was 0.887 and its sensitivity and specificity for the diagnosis of glioma were 86.8% and 80.0%, respectively with the cut-off value of 4.32. The progression-free survival (PFS) and overall survival (OS) of glioma patients with low expression of hsa_circ_0133159 (≤4.32, n = 17) were significantly prolonged as compared with those of glioma patients with high expression of hsa_circ_0133159 (> 4.32, n = 21). The result of univariate analysis showed that the Karnofsky performance status (KPS) score, number of tumor lesions, pathologic grade, recurrence and the relative espression of hsa_circ_0133159 were significantly associated with PFS and OS of patients with glioma (P < 0.05)。Multivariate analysis revealed that relative expression of hsa_circ_0133159 was an independent prognostic factor of glioma [PFS: relative risk = 1.268 (95% confidence interval: 1.007-3.459), P = 0.001; OS: relative risk = 1.252 (95% confidence interval: 1.103-2.422), P = 0.001].
Conclusion: hsa_circ_0133159 may be used as a new biomarker for the diagnosis and prognostic evaluation of glioma.
关键词
胶质瘤 /
环状RNA /
hsa_circ_0133159 /
受试者工作特征曲线 /
诊断 /
预后
Key words
Glioma /
Circular RNA /
hsa_circ_0133159 /
Receiver operating characteristic curve /
Diagnosis /
Prognosis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LOUIS DN, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6):803-820.
[2] JOHANSEN TABER KA, DICKINSON BD, WILSON M. The promise and challenges of next-generation genome sequencing for clinical care[J]. JAMA Intern Med, 2014, 174(2):275-280.
[3] APPIN CL, BRAT DJ. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis[J]. Adv Anat Pathol, 2015, 22(1):50-58.
[4] ADAMCZYK LA, WILLIAMS H, FRANKOW A, et al. Current understanding of circulating tumor cells- potential value in malignancies of the central nervous system[J/OL]. Front Neurol, 2015, 6:174(2015-08-10)[2017-11-19]. https://doi.org/10.3389/fneur.2015.00174. DOI:10.3389/fneur.2015.00174.
[5] MRUGALA MM. Advances and challenges in the treatment of glioblastoma: a clinician’s perspective[J]. Discov Med, 2013, 15(83):221-230.
[6] QU S, YANG X, LI X, et al. Circular RNA: a new star of noncoding RNAs[J]. Cancer Lett, 2015, 365(2):141-148.
[7] LUKIW WJ. Circular RNA (circRNA) in Alzheimer’s disease (AD)[J/OL]. Front Genet, 2013, 4:307(2013-12-31)[2017-11-19]. http://doi.org/10.3389/fgene.2013.00307. DOI:10.3389/fgene.2013.00307.
[8] BURD CE, JECK WR, LIU Y, et al. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk[J/OL]. PLoS Genet, 2010, 6(12):e1001233(2010-12-02)[2017-11-19]. https://doi.org/10.1371/journal.pgen.1001233. DOI:10.1371/journal.pgen.1001233.
[9] GUO LL, SONG CH, WANG P, et al. Competing endogenous RNA networks and gastric cancer[J]. World J Gastroenterol, 2015, 21(41):11680-11687.
[10] LI Y, ZHENG Q, BAO C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis[J]. Cell Res, 2015, 25(8):981-984.
[11] PETKOVIC S, MüLLER S. RNA circularization strategies in vivo and in vitro[J]. Nucleic Acids Res, 2015, 43(4):2454-2465.
[12] LOUIS DN, OHGAKI H, WIESTLER OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007; 114(2):97-109.
[13] HSU MT, COCA-PRADOS M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells[J]. Nature, 1979, 280(5720):339-340.
[14] LI P, CHEN S, CHEN H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer[J]. Clin Chim Acta, 2015, 444:132-136.
[15] WENG W, WEI Q, TODEN S, et al. Circular RNA ciRS-7-a promising prognostic biomarker and a potential therapeutic target in colorectal cancer[J]. Clin Cancer Res, 2017, 23(14):3918-3928.
[16] SHANG X, LI G, LIU H, et al. Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular rna biomarker, is involved in hepatocellular crcinoma development[J/OL]. Medicine (Baltimore), 2016, 95(22):e3811(2016-01-03)[2017-11-19]. http://doi.org/10.1097/MD.0000000000003811. DOI:10.1097/MD.0000000000003811.
[17] YIN WB, YAN MG, FANG X, et al. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection[J/OL]. Clin Chim Acta, 2017, pii:S0009-8981(17)30407-2(2017-10-16)[2017-11-19]. https://doi.org/10.1016/j.cca.2017.10.011. DOI: 10.1016/j.cca.2017.10.011.
[18] ZHU X, WANG X, WEI S, et al. hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma[J]. FEBS J, 2017, 284(14):2170-2182.
[19] ZHU J, YE J, ZHANG L, et al. Differential expression of circular RNAs in glioblastoma multiforme and its correlation with prognosis[J]. Transl Oncol, 2017, 10(2):271-279.
[20] SHI Y, PING YF, ZHOU W, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth[J/OL]. Nat Commun, 2017, 8:15080(2017-01-01)[2017-11-19]. DOI:10.1038/ncomms15080. http://doi.org/10.1038/ncomms15080.
PDF(2244 KB)
